Jie (Jay) Song, PhD, MSc, is a faculty fellow in the Department of Chemistry at Emory College of Arts and Sciences, and a GRA principal investigator with Georgia Research Alliance. Dr. Song's expertise is in biomolecular engineering for drug discovery and development. In collaboration with researchers throughout Emory University and with multiple institutions in the nation, Dr. Song works on the clinical translation of patented anti-cancer nanodrugs that use unprecedented mechanisms of action to selectively kill cancers with minimal side effects. He also leads the development of novel theranostic nanomaterials for targeted imaging and therapy for cancer patients.
Dr. Song is the founder of a cancer nanodrug company, NanoV Therapeutics, which is under the support of the Georgia Research Alliance with a joint effort from Emory University and Georgia Institute of Technology to translate first-of-its-kind anti-cancer drugs into clinics.
He is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He serves as a member of the review panel in the Biomaterials program at the National Science Foundation.
Education
Dr. Song earned his PhD in Catalysis and Materials from Emory University in Atlanta, Georgia, where he trained extensively in the synthesis and characterization of advanced functional materials. He completed a postdoctoral fellowship in biomolecular engineering and nanotechnology, carrying out the preclinical studies of bioconjugated nanoparticles for cancer molecular imaging and targeted drug delivery with the aim to find their therapeutic applications at the Wallace H. Coulter Department of Biomedical Engineering of Georgia Institute of Technology and Emory Medical School. Prior to obtaining his PhD, he received his BSc from Shandong University and MSc from Lanzhou University in China.
Titles & Roles
Faculty Fellow, Department of Chemistry
Emory College of Arts and Sciences
Professional Memberships
Dr. Song is an active member of the American Association for Cancer Research. He is also a member of Biomedical Engineering Society, American Chemical Society and Materials Research Society.
Research
Dr. Song conducts cross-disciplinary investigation of biomedicine for cancer patients at Winship, using innovative concepts from chemistry, biology and nanotechnology to engineer small molecules and large biologics as novel tools for imaging and treatment of cancers and other diseases.
His research in precision nanomedicine entails designs for the synthesis of nanoscale materials for catalysis and biocompatible materials for early detection of cancers and targeted delivery of therapeutics.
He serves as principle investigator on a project for developing catalytic anti-cancer drugs to overcome drug-resistance using nanotechnology. He is co-investigating several projects related to detection and treatment of highly-aggressive brain cancers using targeted small molecules and engineered nanotherapeutics.
Publications
Dr. Song's commitment to science has yielded numerous high-quality publications including high-impact papers in leading journals, three patents (two filed), and one book chapter (Springer). He served as the leading editor for a book by Elsevier, and serves as a frequent judicial reviewer for dozens of top journals. He has chaired symposia at national and international conferences and forums, and is frequently invited to deliver talks at international meetings and universities.
YK Chae, WB Kim, AA Davis, LC Park, JF Anker, NI Simon, K Rhee, J Song, A Cho, S Chang, T Ko, M Oh, M Bhave, P Viveiros
08/01/2020
Awards
Dr. Song has been recognized with a number of awards including the American Chemical Society Merit Award, the Appreciation Award, and the Gordon Research Conference Travel Award among others.
